22nd Oct 2009 07:00
AGI Therapeutics plc
Changes to Executive Team
Dublin, Ireland, 22 October 2009 - AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical development company, announces today that Dr David Young, President of US Operations, and Dr Sian Bigora, Vice President, Clinical Research and Regulatory Affairs, are to leave the Company in the next few weeks. Dr Young will remain as a director of the Board of AGI Therapeutics, plc.
Dr John Devane, CEO of AGI Therapeutics, commented: "We want to thank both David and Sian for their contribution to all aspects of our business and wish them every success in the future. We are particularly pleased that David will remain on our Board which will ensure we continue to receive his counsel on our US regulatory strategy for products being developed as part of our new business plan. We continue to make good progress on developing the operational plans and intellectual property positions that will support those projects which will be the focus of our development efforts over the coming years."
End
Contact Information:
|
AGI Therapeutics plc. |
Tel: +353 1 449 3254 |
|
David Kelly, Chief Financial Officer |
|
|
Financial Dynamics - UK |
Tel: +44 (0) 20 7269 7182 |
|
Jonathan Birt/John Dineen |
|
|
Financial Dynamics - Ireland |
Tel: +353 1 663 3607 |
|
Niamh Lyons |
|
|
Piper Jaffray Limited Neil Mackison Will Carnwath |
Tel: +44 (0) 20 3142 8700 |
|
Davy John Frain |
Tel: +353 1 614 8761 |
For further information please see www.agitherapeutics.com.
Notes to Editors:
About AGI Therapeutics plc
AGI is a specialty pharmaceutical company which is focused on the development and commercialisation of differentiated specialty drug products to treat unmet medical needs, including conditions which qualify for Orphan drug status.
The company has a portfolio of product candidates derived from its Known Molecular Entity (KME™) approach to drug re-profiling and development and aims to bring its products to the market either directly or through out-licensing or other partnering arrangements.
AGI's common shares are listed on the Alternative Investment Market of the London Stock Exchange (AIM) and on the Irish Enterprise Exchange of the Irish Stock Market (IEX) as AGI.
For further information please see www.agitherapeutics.com.
Statements contained within this press release may contain forward-looking comments which involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', or 'continue'. Predictions and forward-looking references in this press release are subject to the satisfactory progress of research which is, by nature, unpredictable. Forward projections reflect management's best estimates based on information available at the time of issue.
Related Shares:
Potentially Ai